Myasthenia Gravis News

Myasthenia Gravis News

Our mission is to provide you with the latest science, research, and clinical updates on Myasthenia Gravis. We are a free online resource dedicated to serving the patient community.

International
English
Online/Digital

Outlet metrics

Domain Authority
32
Ranking

Global

#803921

United States

#216460

Health/Health Conditions and Concerns

#560

Traffic sources
Monthly visitors

Articles

  • 1 week ago | myastheniagravisnews.com | Mark Harrington

    Living with myasthenia gravis (MG) has changed important parts of my life. It has taken things from me that I thought were permanent, such as my physical strength. My previous ability to plan my days with confidence no longer exists. Most difficult of all, MG has made me distrust our healthcare system here in the U.S.However, a new me has arisen phoenixlike from the ashes of my pre-MG life. Upon reflection, I see the new me as a better man.

  • 3 weeks ago | myastheniagravisnews.com | Mark Harrington

    Living with a rare disease is difficult enough, but in the United States, patients fight not only their illness, but also the healthcare system that’s supposed to help them. I was diagnosed with myasthenia gravis (MG) five years ago this month. Managing it requires specialized care, regular treatment, and access to breakthrough medications.

  • 1 month ago | myastheniagravisnews.com | Steve Bryson

    Using tears to test for self-reactive antibodies to help diagnose ocular myasthenia gravis (OMG) is more accurate than using blood samples, according to a study that found nearly all patients who tested negative for these antibodies in the blood had a positive result in tears. “Tear-based testing offers a promising alternative for diagnosing [blood]-negative OMG cases,” the researchers wrote.

  • 1 month ago | myastheniagravisnews.com | Marisa Wexler

    A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common among girls than boys, and in Black children over white children. “Understanding the incidence and prevalence of JMG is crucial for optimizing its management.

  • 1 month ago | myastheniagravisnews.com | Steve Bryson

    Enrollment is open in an investigator-initiated clinical trial to evaluate cell therapy NKX019 in people with myasthenia gravis (MG). Nkarta, the therapy’s developer, made the announcement in a company press release. Researchers at the University of California, Irvine, and the University of Kansas Medical Center are leading the open-label Phase 1 trial, which was given the go-ahead by the U.S. Food and Drug Administration late last year.